Kiniksa Pharmaceuticals 3Q 2026: Revenue $285.97M, Net income $47.35M, EPS $0.56— 10-Q Summary

What happened

Kiniksa Pharmaceuticals reported third-quarter 2026 revenue of $285.97 million, up 58.1% from a year earlier. Net income rose to $47.35 million and diluted earnings per share, which means profit per share, reached $0.56, helped mainly by more patients receiving ARCALYST.

Confirmed

Global impact / market context

ARCALYST brought in most of the growth, so the company's sales depend heavily on one drug. Higher promotional spending, including a direct-to-consumer campaign, raises costs now but aims to add patients and revenue, so investors will weigh patient growth against marketing expense.

Analyst inference

The company is spending more on sales and marketing while funding late-stage trials, including the Phase 3 PASTORALE study of KPL-387 with results expected in the second half of 2027. Shares reflect expectations about whether ARCALYST growth funds that pipeline without extra borrowing.

Analyst inference

What to watch

1. The company expects results from its pivotal Phase 3 PASTORALE trial of KPL-387 in the second half of 2027, a key readout for the pipeline beyond ARCALYST. Confirmed
2. A Phase 2 study is testing whether patients can switch to KPL-387 alone, and a Phase 1 trial of KPL-1161 is expected to start by year-end 2026. Proposed
3. Watch whether higher sales and marketing spending, including the direct-to-consumer campaign, keeps adding ARCALYST patients fast enough to offset those added costs. Analyst inference

Evidence

• Original source link unavailable